يعرض 1 - 10 نتائج من 17 نتيجة بحث عن '"pediatric meningioma"', وقت الاستعلام: 0.97s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المساهمون: Esposito, Silvia, Marucci, Gianluca, Antonelli, Manila, Miele, Evelina, Modena, Piergiorgio, Giagnacovo, Marzia, Massimino, Maura, Biassoni, Veronica, Taddei, Matilde, Schiariti, Marco Paolo, Doniselli, Fabio Martino, Moscatelli, Marco, Chiapparini, Luisa, Pollo, Bianca

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36292056; info:eu-repo/semantics/altIdentifier/wos/WOS:000872677600001; volume:12; issue:10; journal:DIAGNOSTICS; https://hdl.handle.net/11573/1673000Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85140655808

  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المساهمون: Rombi, B, Ruggi, A, Sardi, I, Zucchelli, M, Scagnet, M, Toni, F, Cammelli, S, Giulietti, G, Fabbri, Vp, Gianno, F, Amichetti, M, Yock, Ti, Morganti, Ag, Pession, A, Melchionda, F

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33682333; info:eu-repo/semantics/altIdentifier/wos/WOS:000625893400001; volume:68; issue:5; journal:PEDIATRIC BLOOD & CANCER; https://hdl.handle.net/11573/1702531Test

  6. 6
    دورية أكاديمية

    المساهمون: Barbara Rombi, Alessandro Ruggi, Iacopo Sardi, Mino Zucchelli, Mirko Scagnet, Francesco Toni, Silvia Cammelli, Giulia Giulietti, Viscardo Paolo Fabbri, Francesca Gianno, Maurizio Amichetti, Torunn Ingrid Yock, Alessio Giuseppe Morganti, Andrea Pession, Fraia Melchionda

    وصف الملف: ELETTRONICO

    العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000625893400001; volume:1; firstpage:1; lastpage:6; numberofpages:6; journal:PEDIATRIC BLOOD & CANCER; https://hdl.handle.net/11585/861047Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85102200212

  7. 7
    دورية أكاديمية

    المساهمون: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Beyin ve Sinir Cerrahisi Anabilim Dalı., Bursa Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı., orcid:0000-0003-1359-4445, orcid:0000-0001-7620-2571, orcid:0000-0002-5771-7649, orcid:0000-0002-8211-6175, orcid:0000-0002-9038-0515, orcid:0000-0001-5472-9065, Tunçbilekli, Yağmur, Kasap, Reyhan, Özşen, Mine, Yirmibeş, Selin, Tolunay, Şahsine, Taşkapılıoğlu, M. Özgür

    وصف الملف: application/pdf

    العلاقة: Makale - Uluslararası Hakemli Dergi; Uludağ Üniversitesi Tıp Fakültesi Dergisi / Journal of Uludag University Medical Faculty; Tunçbilek, Y. vd. (2021). ''9 yaşında bir çocukta servikal meningioma: Bir olgu sunumu''. Uludağ Üniversitesi Tıp Fakültesi Dergisi, 47(2), 287-289.; https://dergipark.org.tr/tr/download/article-file/1688704Test; https://doi.org/10.32708/uutfd.910723Test; http://hdl.handle.net/11452/27532Test; 287; 289; 47

  8. 8
  9. 9
  10. 10
    تقرير

    المصدر: Pal K, Cao Y, Gaisina IN, Bhattacharya S, Dutta SK, Wang E, Gunosewoyo H, Kozikowski AP, Billadeau DD, Mukhopadhyay D. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Ther. 2014 Feb;13(2):285-96. doi: 10.1158/1535-7163.MCT-13-0681. Epub 2013 Dec 10.
    Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 Oct 1;380(2):384-392. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14.
    Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP. Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.
    Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ. GSK-3beta inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents. Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29.
    Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma. Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.
    Wu X, Stenson M, Abeykoon J, Nowakowski K, Zhang L, Lawson J, Wellik L, Li Y, Krull J, Wenzl K, Novak AJ, Ansell SM, Bishop GA, Billadeau DD, Peng KW, Giles F, Schmitt DM, Witzig TE. Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. Blood. 2019 Jul 25;134(4):363-373. doi: 10.1182/blood.2018874560. Epub 2019 May 17.
    Ding L, Madamsetty VS, Kiers S, Alekhina O, Ugolkov A, Dube J, Zhang Y, Zhang JS, Wang E, Dutta SK, Schmitt DM, Giles FJ, Kozikowski AP, Mazar AP, Mukhopadhyay D, Billadeau DD. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Clin Cancer Res. 2019 Nov 1;25(21):6452-6462. doi: 10.1158/1078-0432.CCR-19-0799. Epub 2019 Sep 18. Erratum In: Clin Cancer Res. 2021 Jul 15;27(14):4128.
    Jeffers A, Qin W, Owens S, Koenig KB, Komatsu S, Giles FJ, Schmitt DM, Idell S, Tucker TA. Glycogen Synthase Kinase-3beta Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis. Sci Rep. 2019 Dec 12;9(1):18925. doi: 10.1038/s41598-019-55176-w.
    Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar AP, Giles FJ, Ugolkov A, Tomita Y. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. doi: 10.1038/s41598-019-56461-4.
    Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3beta as a Target for the Treatment of Cancer. Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4.
    Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.